apatinib

Phase 3Small molecule

apatinib is one of 543 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

264

Total Trials

Active Trials

542

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Gastric AdenocarcinomaUnknown status

Ovarian CarcinomaNot yet recruiting

Intrahepatic CholangiocarcinomaRecruiting

Metastatic Prostate CancerActive, not recruiting

Lung AdenocarcinomaUnknown status

Non-Small Cell Lung CancerWithdrawn

Breast CancerActive, not recruiting

Pancreatic CancerUnknown status

Hepatocellular CarcinomaCompleted

Esophageal Squamous Cell CarcinomaPhase 2

Recruiting

Gastric AdenocarcinomaPhase 2

Unknown status

Ovarian CarcinomaPhase 2

Not yet recruiting

Intrahepatic CholangiocarcinomaPhase 2

Recruiting

Metastatic Prostate CancerPreclinical

Active, not recruiting

Lung AdenocarcinomaPhase 2

Unknown status

Non-Small Cell Lung CancerPhase 3

Withdrawn

Breast CancerPhase 3

Active, not recruiting

Pancreatic CancerPhase 2

Unknown status

Hepatocellular CarcinomaPhase 3

Completed

Showing 10 of 30 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Phase 3

15 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Tricor

JJagotec

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

First-Line Treatment

NCT06694324

Phase 3Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06351020

Phase 2Not yet recruiting

Ovarian Carcinoma

NCT06081595

Phase 2Recruiting

Breast Cancer

NCT05447702

Phase 2Recruiting

Breast Cancer

NCT06418594

Q1 2027

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT07031154

Clinical

Trials by Indication[1]

Gastric Cancer28 trials

Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)

Unknown status·—·Phase 2·NCT02596256·80 enrolled

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03026881·24 enrolled

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

Unknown status·—·Phase 2·NCT03007446·20 enrolled

Show 25 more trials

Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 4·NCT05029453·60 enrolled

Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer

Unknown status·HHebei Medical University·Phase 2/3·NCT02509806·48 enrolled

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

Unknown status·FFudan University·Phase 3·NCT03889626·242 enrolled

Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT02697838·20 enrolled

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer

Unknown status·—·Phase 2·NCT02525237·30 enrolled

Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer

Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 3·NCT02537171·40 enrolled

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03472365·67 enrolled

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Active, not recruiting·RRuijin Hospital·Phase 2·NCT06693128·80 enrolled

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Unknown status·HHebei Medical University·Phase 2·NCT03718624·36 enrolled

Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.

Unknown status·SSun Yat-sen University·Phase 2·NCT03144843·110 enrolled

HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

Terminated·WWuhan University·N/A·NCT03349827·20 enrolled

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Recruiting·—··NCT06485271·504 enrolled

Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Completed·FFudan University·Phase 2/3·NCT00970138·141 enrolled

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Active, not recruiting·RRuijin Hospital·Phase 2/3·NCT04208347·580 enrolled

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT04121039·116 enrolled

A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer

Unknown status·—·Phase 2·NCT03271073·20 enrolled

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Completed·QQilu Hospital of Shandong University·Phase 2·NCT03878472·25 enrolled

A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer

Unknown status·SShanghai Zhongshan Hospital·Phase 2/3·NCT02409199·66 enrolled

Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer

Unknown status·DDongMa·N/A·NCT03255811·40 enrolled

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03813784·885 enrolled

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Unknown status·HHuazhong University of Science and Technology·Phase 3·NCT03598348·288 enrolled

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Recruiting·FFujian Cancer Hospital·Phase 2/3·NCT05699655·130 enrolled

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06385873·32 enrolled

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04267549·47 enrolled

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02485015·80 enrolled

Hepatocellular Carcinoma14 trials

The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus

Unknown status·GGuangxi Medical University·Phase 2·NCT03520257·50 enrolled

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT04014101·40 enrolled

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT03510416·22 enrolled

Show 11 more trials

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03046979·30 enrolled

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 1/2·NCT02942329·60 enrolled

Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT03398122·248 enrolled

A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2/3·NCT07309419·222 enrolled

A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Unknown status·PPeking University Cancer Hospital & Institute·Phase 1/2·NCT02727309·30 enrolled

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT02329860·400 enrolled

A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT01192971·121 enrolled

Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT03114085·170 enrolled

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Not yet recruiting·ZZhujiang Hospital·Phase 2·NCT06546280·38 enrolled

SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06538935·80 enrolled

The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients

Unknown status·GGuangxi Medical University·Phase 2·NCT03511703·40 enrolled

Non-Small Cell Lung Cancer11 trials

The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Unknown status·TThird Military Medical University·Phase 2·NCT02733107·25 enrolled

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03777124·25 enrolled

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Unknown status·—·Phase 2·NCT04506242·74 enrolled

Show 8 more trials

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT01270386·136 enrolled

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT02332512·417 enrolled

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

Withdrawn·XXinqiao Hospital of Chongqing·Phase 4·NCT03792503

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Withdrawn·XXinqiao Hospital of Chongqing·Phase 2·NCT03190239

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Unknown status·—·Phase 2·NCT03416231·20 enrolled

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03083041·210 enrolled

Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

Unknown status·SSun Yat-sen University·Phase 3·NCT01287962·480 enrolled

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07031154·43 enrolled

Breast Cancer11 trials

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07371910·200 enrolled

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Recruiting·WWest China Hospital·Phase 2·NCT05447702·35 enrolled

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Completed·FFudan University·Phase 2·NCT01653561·20 enrolled

Show 8 more trials

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Unknown status·HHebei Medical University Fourth Hospital·Phase 2/3·NCT03580395·200 enrolled

Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer

Completed·GGuangdong Provincial People's Hospital·Phase 2·NCT03243838·31 enrolled

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Unknown status·HHebei Medical University Fourth Hospital·Phase 2·NCT03086785·120 enrolled

Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer

Unknown status·YYan Li·Phase 2·NCT03457467·30 enrolled

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04335006·80 enrolled

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Completed·PPeking University Cancer Hospital & Institute·Phase 2·NCT02878057·30 enrolled

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Recruiting·—·Phase 2·NCT06418594·30 enrolled

Ovarian Cancer9 trials

A Study of Apatinib Treatment in for Advanced Ovarian Cancer

Unknown status·TThe People's Hospital of Leshan·Phase 2·NCT03393507·34 enrolled

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Unknown status·YYang Zhijun·Phase 2·NCT03298074·60 enrolled

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04068974·28 enrolled

Show 6 more trials

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03942068·35 enrolled

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04383977·54 enrolled

Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy

Unknown status·—·Phase 2·NCT03547375·69 enrolled

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Terminated·FFirst Affiliated Hospital of Harbin Medical University·Phase 2·NCT03587129·1 enrolled

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT03262545·60 enrolled

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Completed·SSun Yat-sen University·Phase 2·NCT02867956·35 enrolled

66 more indications

Thyroid Cancer6 trials

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Completed·PPeking Union Medical College Hospital·Phase 2·NCT02731352·20 enrolled

Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

Unknown status·—·Phase 2·NCT03300765·20 enrolled

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting·WWest China Hospital·Phase 2·NCT06482086·75 enrolled

Show 3 more trials

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT03048877·118 enrolled

A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03199677·40 enrolled

Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers

Unknown status·NNanjing First Hospital, Nanjing Medical University·Phase 2·NCT04180007·10 enrolled

Camrelizumab5 trials

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Unknown status·HHuiqiang Huang·Phase 1/2·NCT04476459·33 enrolled

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

Completed·PPeking Union Medical College Hospital·Phase 2·NCT04047017·20 enrolled

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT05198609·214 enrolled

Show 2 more trials

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT05171309·35 enrolled

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Unknown status·SSun Yat-sen University·Phase 2·NCT04454905·50 enrolled

Esophageal Squamous Cell Carcinoma5 trials

Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

Terminated·PPeking University·Phase 2·NCT03251417·11 enrolled

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Completed·PPeking University·Phase 1·NCT02645864·12 enrolled

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed·FFudan University·Phase 2·NCT03274011·40 enrolled

Show 2 more trials

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06339619·32 enrolled

Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT03193424·120 enrolled

Small Cell Lung Cancer5 trials

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06786312·34 enrolled

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

Unknown status·—·Phase 3·NCT03651219·90 enrolled

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Unknown status·TTianjin Medical University Second Hospital·Phase 1/2·NCT04659785·53 enrolled

Show 2 more trials

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04453930·60 enrolled

A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer

Completed·TThe First Hospital of Jilin University·Phase 2·NCT03547804·31 enrolled

Apatinib4 trials

A Study To Test The Effect Of Apatinib On P450 Enzymes

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03245307·20 enrolled

Study of the Combination of Apatinib and POF

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03707639·26 enrolled

Phase I Study of the Combination of Apatinib and POF

Unknown status·FFujian Cancer Hospital·Phase 1·NCT03244774·18 enrolled

Show 1 more trial

A Phase II Study of Apatinib in STS Patients

Unknown status·SShanghai Jiao Tong University Affiliated Sixth People's Hospital·Phase 2·NCT03064243·53 enrolled

Triple-Negative Breast Cancer4 trials

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03348098·20 enrolled

This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT03650738·60 enrolled

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT03775928·80 enrolled

Show 1 more trial

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03735082·29 enrolled

Glioma4 trials

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Unknown status·TThe First Affiliated Hospital of Zhengzhou University··NCT04216550·600 enrolled

TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT

Unknown status·TThe Second Hospital of Hebei Medical University·Phase 2·NCT03741244·211 enrolled

A Study of Apatinib in Recurrent or Recurrent High-grade Glioma

Unknown status·WWest China Hospital·Phase 2·NCT03390062·30 enrolled

Show 1 more trial

Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas

Unknown status·WWuHui·Phase 2·NCT04253873·40 enrolled

Colorectal Cancer4 trials

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 1/2·NCT04067986·62 enrolled

Apatinib in Refractory Colorectal Cancer

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT03190616·54 enrolled

Apatinib for Resectable Colorectal Cancer

Withdrawn·—·N/A·NCT03228043

Show 1 more trial

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Completed·HHuashan Hospital·Phase 3·NCT03365765·63 enrolled

Chemotherapy4 trials

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Unknown status·TThe First Hospital of Jilin University·Phase 2·NCT03758677·30 enrolled

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT03671265·20 enrolled

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03121846·80 enrolled

Show 1 more trial

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03092895·157 enrolled

Lung Adenocarcinoma3 trials

Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03376737·120 enrolled

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Unknown status·FFirst Affiliated Hospital of Kunming Medical University·Phase 2·NCT02704767·60 enrolled

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02493582·400 enrolled

Lung Cancer3 trials

The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer

Unknown status·JJunling Li·Phase 2·NCT03129698·52 enrolled

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Unknown status·SSun Yat-sen University·Phase 3·NCT02824458·246 enrolled

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

Unknown status·—·Phase 2·NCT02980809·60 enrolled

Nasopharyngeal Carcinoma3 trials

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Completed·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT03180476·21 enrolled

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04548271·25 enrolled

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04547088·27 enrolled

First-line Treatment3 trials

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Unknown status·WWest China Hospital·Phase 1/2·NCT03201146·48 enrolled

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Withdrawn·SSun Yat-sen University·Phase 2·NCT03164694

First-line Treatment of Advanced/unresectable DDLPS

Not yet recruiting·FFudan University·Phase 2·NCT06694324·49 enrolled

Osteosarcoma3 trials

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

Unknown status·RRuijin Hospital·Phase 2·NCT03742193·43 enrolled

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

Suspended·PPeking University People's Hospital·Phase 2·NCT04824352·44 enrolled

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

Completed·GGUO WEI·Phase 2/3·NCT02711007·37 enrolled

Second-line Treatment3 trials

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Unknown status·FFeng Wang·Phase 3·NCT05049681·234 enrolled

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Unknown status·—·Phase 2·NCT03116555·37 enrolled

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03030937·74 enrolled

Treatment3 trials

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 1/2·NCT04133337·20 enrolled

Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04126993·80 enrolled

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03417895·59 enrolled

Head and Neck Cancer2 trials

Apatinib for Advanced Non-squamous Head and Neck Cancer

Unknown status·—·Phase 2·NCT02989259·30 enrolled

The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer

Unknown status·—·Phase 2·NCT02943252·30 enrolled

Cervical Cancer2 trials

Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer

Unknown status·TThird Military Medical University·N/A·NCT03029013·30 enrolled

Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.

Unknown status·—·Phase 2·NCT03546855·69 enrolled

Unresectable2 trials

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

Unknown status·YYanqiao Zhang·Phase 2·NCT03793725·30 enrolled

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05853172·30 enrolled

Patients With Advanced Solid Tumors2 trials

Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

Unknown status·TThe First People's Hospital of Lianyungang·Phase 1/2·NCT02844881·60 enrolled

Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors

Unknown status· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT03243643·80 enrolled

Gastric Adenocarcinoma2 trials

Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03788174·26 enrolled

XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma

Unknown status·—·Phase 1/2·NCT03599778·52 enrolled

Esophagus Cancer2 trials

Apatinib Treatment for Advanced Esophagus Cancer

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03170310·60 enrolled

Apatinib as First -Line Treatment for Advanced Esophagus Cancer

Unknown status·—·Phase 2·NCT03542422·50 enrolled

Intrahepatic Cholangiocarcinoma2 trials

A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT03521219·30 enrolled

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Recruiting·LLei ZHAO·Phase 2·NCT06296563·20 enrolled

Non-squamous NSCLC2 trials

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

Unknown status·HHebei Medical University Fourth Hospital·N/A·NCT03634059·80 enrolled

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Unknown status·JJunling Li·Phase 2·NCT04670913·30 enrolled

Melanoma2 trials

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03383237·20 enrolled

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT03422445·30 enrolled

Adjuvant Therapy2 trials

Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT03261791·30 enrolled

A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT03609489·40 enrolled

Biliary Tract Cancer2 trials

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Completed·—·Phase 2·NCT04720131·28 enrolled

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

Unknown status·SSun Yat-sen University·Phase 2·NCT03144856·39 enrolled

Adenocarcinoma2 trials

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

Unknown status·SSir Run Run Shaw Hospital·Phase 1·NCT03071042·12 enrolled

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Unknown status·HHebei Medical University·Phase 2·NCT03349866·48 enrolled

Esophageal Cancer2 trials

An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2/3·NCT03285906·30 enrolled

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Unknown status·SShanghai Chest Hospital·Phase 2·NCT03913182·39 enrolled

Soft Tissue Sarcoma2 trials

Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial

Withdrawn·PPeking University People's Hospital·Phase 2·NCT03104335

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Unknown status·HHunan Cancer Hospital·Phase 2·NCT04239443·120 enrolled

Esophageal Squamous Cell Cancer2 trials

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03603756·45 enrolled

Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Unknown status·TThe First Affiliated Hospital of Anhui Medical University·Phase 2·NCT03224221·189 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma

Unknown status·GGuangzhou Institute of Respiratory Disease·Phase 2·NCT03709953·33 enrolled

Microwave Ablation1 trial

A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

Not yet recruiting·—·Phase 2·NCT06537505·60 enrolled

Advanced NSCLC1 trial

Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC

Unknown status·—·Phase 2·NCT03411967·20 enrolled

Metastasis1 trial

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Withdrawn·SSun Yat-sen University·Phase 2·NCT04682249

Conversion Therapy1 trial

Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer

Recruiting·—·Phase 2·NCT07353684·49 enrolled

Metastatic Colorectal Cancer1 trial

Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer

Unknown status·LLiqiang Zhong·Phase 2·NCT03412994·60 enrolled

Head and Neck1 trial

Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies

Unknown status·CChina International Medical Foundation·Phase 1/2·NCT03654612·30 enrolled

First Line Therapy1 trial

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03764293·543 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Active, not recruiting·LLaNova Medicines Zhejiang Co., Ltd.·Phase 3·NCT06351020·387 enrolled

Liver Cancer1 trial

Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study

Unknown status·ZZhejiang Cancer Hospital·Phase 2/3·NCT02702323·40 enrolled

Unknown status·UUnknown Sponsor·Phase 2·NCT03801200·90 enrolled

Unresectable Biliary Tract Carcinoma1 trial

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06749730·63 enrolled

Angiogenesis1 trial

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Unknown status·FFudan University·Phase 1·NCT00633490·18 enrolled

Adverse Drug Reactions1 trial

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Unknown status·SSun Yat-sen University·Phase 4·NCT03475589·217 enrolled

Gallbladder Carcinoma1 trial

Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma

Unknown status·—·Phase 2·NCT03702491·138 enrolled

Advanced1 trial

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07157969·300 enrolled

Glioblastoma1 trial

Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma

Unknown status·FFuzhou General Hospital··NCT03567135·60 enrolled

Pancreatic Carcinoma1 trial

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04415385·48 enrolled

Locally Advanced1 trial

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT03355612·456 enrolled

Metastatic Prostate Cancer1 trial

Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer

Completed·SSichuan Provincial People's Hospital·N/A·NCT02998242·40 enrolled

Pancreatic Cancer1 trial

A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT02863367·30 enrolled

Oral Squamous Cell Carcinoma1 trial

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Completed·SShanghai Jiao Tong University School of Medicine·Phase 1·NCT04393506·21 enrolled

Neoadjuvant1 trial

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT05069857·46 enrolled

Carcinoma1 trial

Apatinib for Advanced Lung Squmamous Carcinoma

Unknown status·—·Phase 4·NCT03725423·50 enrolled

Ovarian Carcinoma1 trial

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Not yet recruiting·JJin LI·Phase 2·NCT06081595·54 enrolled

Metastatic Cancer1 trial

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Completed·EElevar Therapeutics·Phase 1·NCT03396211·30 enrolled

Non-Squamous1 trial

Apatinib in Advanced Non-squamous，NSCLC

Unknown status·JJian Fang··NCT03376191·100 enrolled

Lymphoma1 trial

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Completed·ZZhengzhou University·Phase 4·NCT03376958·32 enrolled

PTCL1 trial

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown status·RRuijin Hospital·Phase 1/2·NCT05559008·116 enrolled

Recurrent or Refractory1 trial

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Completed·RRongjie Tao·Phase 2·NCT03660761·25 enrolled

Brain Injury1 trial

Effect and Safety of Apatinib on Radiation-Induced Brain Injury

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04152681·36 enrolled

Adrenal Cortical Carcinoma1 trial

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Recruiting·WWest China Hospital·Phase 2·NCT06831175·28 enrolled

Adenoid Cystic Carcinoma1 trial

Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma

Unknown status·SShanghai Proton and Heavy Ion Center·Phase 2·NCT02942693·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 264 trial records for apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LaNova Medicines Zhejiang Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLaNova Medicines Zhejiang Co., Ltd.

apatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Gastric Cancer28 trials

Hepatocellular Carcinoma14 trials

Non-Small Cell Lung Cancer11 trials

Breast Cancer11 trials

Ovarian Cancer9 trials

Thyroid Cancer6 trials

Camrelizumab5 trials

Esophageal Squamous Cell Carcinoma5 trials

Small Cell Lung Cancer5 trials

Apatinib4 trials

Triple-Negative Breast Cancer4 trials

Glioma4 trials

Colorectal Cancer4 trials

Chemotherapy4 trials

Lung Adenocarcinoma3 trials

Lung Cancer3 trials

Nasopharyngeal Carcinoma3 trials

First-line Treatment3 trials

Osteosarcoma3 trials

Second-line Treatment3 trials

Treatment3 trials

Head and Neck Cancer2 trials

Cervical Cancer2 trials

Unresectable2 trials

Patients With Advanced Solid Tumors2 trials

Gastric Adenocarcinoma2 trials

Esophagus Cancer2 trials

Intrahepatic Cholangiocarcinoma2 trials

Non-squamous NSCLC2 trials

Melanoma2 trials

Adjuvant Therapy2 trials

Biliary Tract Cancer2 trials

Adenocarcinoma2 trials

Esophageal Cancer2 trials

Soft Tissue Sarcoma2 trials

Esophageal Squamous Cell Cancer2 trials

Efficacy and Safety1 trial

Microwave Ablation1 trial

Advanced NSCLC1 trial

Metastasis1 trial

Conversion Therapy1 trial

Metastatic Colorectal Cancer1 trial

Head and Neck1 trial

First Line Therapy1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Liver Cancer1 trial

Renal Cell Carcinoma1 trial

Cholangiocarcinoma1 trial

Radiotherapy1 trial

Unresectable Biliary Tract Carcinoma1 trial

Angiogenesis1 trial

Adverse Drug Reactions1 trial

Gallbladder Carcinoma1 trial

Advanced1 trial

Glioblastoma1 trial

Pancreatic Carcinoma1 trial

Locally Advanced1 trial

Metastatic Prostate Cancer1 trial

Pancreatic Cancer1 trial

Oral Squamous Cell Carcinoma1 trial

Neoadjuvant1 trial

Carcinoma1 trial

Ovarian Carcinoma1 trial

Metastatic Cancer1 trial

Non-Squamous1 trial

Lymphoma1 trial

PTCL1 trial

Recurrent or Refractory1 trial

Brain Injury1 trial

Adrenal Cortical Carcinoma1 trial

Adenoid Cystic Carcinoma1 trial

References

Drug Info